Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
University of Connecticut Health Center, Farmington, Connecticut, United States
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
BroMenn Regional Medical Center, Normal, Illinois, United States
Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States
Rush-Copley Cancer Care Center, Aurora, Illinois, United States
Wellstar Cancer Research, Marietta, Georgia, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany
Ospedale Fatebenefratelli, U.O. di Oncologia, Benevento, BN, Italy
Ospedale Pierantoni, Divisione di Oncologia Medica, Forli', FO, Italy
Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy
Ospedale San Martino, Genova, GE, Italy
Divisione di Oncologia Medica, U.S.L.L. 13, Noale, VE, Italy
Ospedale Umberto di Frosinone, Frosinone, FR, Italy
Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy
Ospedale S. Giovanni Calibita Fatebenefratelli, Roma, Italy
Università Cattolica del Sacro Cuore, Dipartimento di Oncologia, Campobasso, CB, Italy
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.